BioXcel Therapeutics (BTAI) Aandelenoverzicht
BioXcel Therapeutics, Inc. is, samen met haar dochteronderneming OnkosXcel Therapeutics LLC, actief als biofarmaceutisch bedrijf dat gebruik maakt van kunstmatige intelligentie om geneesmiddelen te ontwikkelen in de neurowetenschappen en immuno-oncologie in de Verenigde Staten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 0/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
+ 3 meer risico's
BTAI Community Fair Values
Create NarrativeSee what 33 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
BioXcel Therapeutics, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$1.13 |
| 52 Week Hoogtepunt | US$8.08 |
| 52 Week Laag | US$1.01 |
| Bèta | 0.31 |
| 1 maand verandering | 6.60% |
| 3 maanden verandering | -31.93% |
| 1 Jaar Verandering | -18.71% |
| 3 jaar verandering | -99.63% |
| 5 jaar verandering | -99.79% |
| Verandering sinds IPO | -99.36% |
Recent nieuws en updates
BTAI: At Home Agitation Opportunity Will Drive Future Upside Despite Dilution
Analysts have reset BioXcel Therapeutics' blended price target closer to $6, reflecting recent equity dilution while still pointing to what they view as attractive upside from the company's differentiated at home agitation franchise and expanding BXCL501 neuropsychiatry opportunities. Analyst Commentary Recent Street commentary on BioXcel Therapeutics centers on how to balance dilution driven pressure on the share price with what analysts see as meaningful potential around the BXCL501 franchise and the broader neuropsychiatry pipeline.BTAI: At Home Agitation Franchise Will Drive Future Repricing Despite Dilution
Narrative Update The analyst fair value estimate for BioXcel Therapeutics has been adjusted slightly to $14.00 from $14.25, as analysts weigh the recent equity dilution against ongoing views that BXCL501's at-home agitation use and broader neuropsychiatry potential support a higher upside than current trading levels suggest. Analyst Commentary Recent Street research highlights a split view on BioXcel Therapeutics, with some analysts focused on the long-term potential of BXCL501 and others more focused on balance sheet pressure from equity issuance.Recent updates
BTAI: At Home Agitation Opportunity Will Drive Future Upside Despite Dilution
Analysts have reset BioXcel Therapeutics' blended price target closer to $6, reflecting recent equity dilution while still pointing to what they view as attractive upside from the company's differentiated at home agitation franchise and expanding BXCL501 neuropsychiatry opportunities. Analyst Commentary Recent Street commentary on BioXcel Therapeutics centers on how to balance dilution driven pressure on the share price with what analysts see as meaningful potential around the BXCL501 franchise and the broader neuropsychiatry pipeline.BTAI: At Home Agitation Franchise Will Drive Future Repricing Despite Dilution
Narrative Update The analyst fair value estimate for BioXcel Therapeutics has been adjusted slightly to $14.00 from $14.25, as analysts weigh the recent equity dilution against ongoing views that BXCL501's at-home agitation use and broader neuropsychiatry potential support a higher upside than current trading levels suggest. Analyst Commentary Recent Street research highlights a split view on BioXcel Therapeutics, with some analysts focused on the long-term potential of BXCL501 and others more focused on balance sheet pressure from equity issuance.BTAI: At Home Agitation Expansion Will Drive Repricing Despite Dilution Concerns
Analysts now set an updated $14.25 price target for BioXcel Therapeutics, refining their outlook as they weigh enthusiasm around the at-home agitation franchise and expanding BXCL501 options against recent and expected equity dilution. Analyst Commentary Recent Street research reflects a split view on BioXcel Therapeutics, with some analysts emphasizing upside tied to the at-home agitation portfolio and others focusing more on the impact of equity dilution on upside potential.BTAI: At Home Agitation sNDA Will Drive Repricing Despite Equity Dilution Concerns
Analysts have trimmed their fair value estimate for BioXcel Therapeutics from $15.25 to $14.25, reflecting a lower price target after recent Street research highlighted equity dilution as a key concern. Analyst Commentary Bullish Takeaways Bullish analysts still see upside potential even after the price target adjustment to US$6, suggesting they believe current valuation already reflects a good portion of the equity dilution risk.BTAI: At Home Agitation sNDA And Planning Will Drive Repricing Potential
Analysts kept their $15.25 price target for BioXcel Therapeutics unchanged, citing relatively steady modeled fair value, a similar discount rate and revenue outlook, and only modest tweaks to profit margin and future P/E assumptions. What's in the News Completed an updated market opportunity assessment for IGALMI for acute agitation in bipolar disorder or schizophrenia in the at home setting, using insights from the SERENITY At Home study to guide launch planning.BTAI: At Home Agitation Use Expansion Will Drive Repricing Potential
Analysts now see fair value for BioXcel Therapeutics at US$15.25, down from US$16.75. This reflects updated assumptions for growth, profitability and a higher future P/E multiple in their models.BTAI: At Home Agitation Approval Effort Will Drive Repricing Potential
Analysts have revised their price target for BioXcel Therapeutics to US$16.75, with the change largely tied to updated assumptions for the discount rate, profit margin outlook, and a slightly lower future P/E multiple. What's in the News Submitted a supplemental New Drug Application (sNDA) to the U.S. FDA for IGALMI for at home treatment of agitation tied to bipolar disorders or schizophrenia, aiming to expand use beyond healthcare provider supervised settings where there are currently no FDA approved options (Key Developments).BTAI: At Home Agitation sNDA And Safety Data Will Drive Repricing
Analysts have modestly reset their price target for BioXcel Therapeutics to US$16.75. This reflects updated assumptions around discount rate, profit margin, and future P/E that keep their fair value view broadly unchanged.BTAI: At Home Agitation Approval Pathway Will Drive Bullish Repricing
Narrative Update on BioXcel Therapeutics Analysts have modestly lifted their price target on BioXcel Therapeutics, citing a reaffirmed fair value estimate near $16.75 per share, supported by stable long term growth and profitability assumptions, despite a slightly higher discount rate and modestly richer projected valuation multiples. What's in the News Shareholders are scheduled to vote at the December 12, 2025 AGM on an amendment to the certificate of incorporation that would enable a reverse stock split, which may reflect efforts to maintain listing compliance and improve share price optics (company filing).BTAI: Phase 3 At Home Agitation Data Will Drive Bullish Repricing
Analysts have raised their price target on BioXcel Therapeutics to $4 from $2, citing stronger long term risk adjusted sales potential for BXCL501 supported by positive Phase 3 SERENITY At Home data, while still flagging financing uncertainty. Analyst Commentary Analysts updating their models following the SERENITY At Home readout are highlighting both improved long term revenue potential and persistent execution risks that temper the valuation upside.BTAI: Strong Phase 3 Study Results Will Drive Further Market Momentum
Analysts have lowered their fair value estimate for BioXcel Therapeutics from $23.75 to $16.75 per share, citing improved long-term revenue projections and profit margins. This outlook is balanced by ongoing uncertainties related to the company’s financing strategy.BTAI: Upcoming Regulatory Milestones Will Drive Momentum Following Key Phase 3 Success
Analysts have increased their fair value price target for BioXcel Therapeutics from $19 to $23.75, citing improved revenue growth expectations, a higher profit margin forecast, and optimism following positive BXCL501 study results as well as expanded indications. Analyst Commentary Recent analyst updates reflect a mix of optimism and ongoing caution surrounding BioXcel Therapeutics following positive developments for BXCL501 and improving financial projections.
BXCL501 And SERENITY Trials Will Unlock New Treatment Horizons
Advancing Phase III trials and successful SERENITY outcomes could expand market access and boost revenue through FDA approvals and new partnerships.Shareholders May Be More Conservative With BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) CEO Compensation For Now
Key Insights BioXcel Therapeutics will host its Annual General Meeting on 10th of June CEO Vimal Mehta's total...Rendement voor aandeelhouders
| BTAI | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 4.6% | 3.1% | 1.2% |
| 1Y | -18.7% | 34.6% | 28.7% |
Rendement versus industrie: BTAI presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 34.6 % opleverde.
Rendement versus markt: BTAI presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 28.7 % opleverde.
Prijsvolatiliteit
| BTAI volatility | |
|---|---|
| BTAI Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: De aandelenkoers van BTAI is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van BTAI is het afgelopen jaar gedaald van 20% naar 12%, maar is nog steeds hoger dan 75% van de US -aandelen.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2017 | 29 | Vimal Mehta | www.bioxceltherapeutics.com |
BioXcel Therapeutics, Inc, samen met haar dochteronderneming OnkosXcel Therapeutics LLC, is een biofarmaceutisch bedrijf dat gebruik maakt van kunstmatige intelligentie om geneesmiddelen te ontwikkelen in de neurowetenschappen en immuno-oncologie in de Verenigde Staten. Het bedrijf IGALMI, een sublinguale film voor de acute behandeling van agitatie geassocieerd met schizofrenie of bipolaire stoornis I of II bij volwassenen. Het bedrijf ontwikkelt ook zijn neurowetenschappelijke kandidaat BXCL501, een eigen, farmaceutische, oraal oplosbare sublinguale filmformulering van dexmedetomidine in Fase 3 voor de behandeling van agitatie geassocieerd met bipolaire stoornissen, schizofrenie en de ziekte van Alzheimer, evenals opioïde gebruiksstoornis, alcoholgebruiksstoornis met comorbide posttraumatische stressstoornis en acute stressstoornis; BXCL701 is een orale immuunactivator voor onderzoek en heeft de Fase 1b/2a studie voltooid voor de behandeling van agressieve vormen van prostaatkanker, alvleesklierkanker en andere vaste en vloeibare tumoren.
BioXcel Therapeutics, Inc. Samenvatting
| BTAI fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$34.89m |
| Inkomsten(TTM) | -US$75.33m |
| Inkomsten(TTM) | US$680.00k |
Is BTAI overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| BTAI resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$680.00k |
| Kosten van inkomsten | US$433.00k |
| Brutowinst | US$247.00k |
| Overige uitgaven | US$75.58m |
| Inkomsten | -US$75.33m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -2.44 |
| Brutomarge | 36.32% |
| Nettowinstmarge | -11,078.53% |
| Schuld/Eigen Vermogen Verhouding | -95.0% |
Hoe presteerde BTAI op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/26 21:08 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
BioXcel Therapeutics, Inc. wordt gevolgd door 10 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Anita Dushyanth | Berenberg |
| Guyn Kim | BMO Capital Markets Equity Research |
| Alec Stranahan | BofA Global Research |